Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Courèche Kaderbhai"'
Autor:
Alexandre Le Marouille, Emma Petit, Courèche Kaderbhaï, Isabelle Desmoulins, Audrey Hennequin, Didier Mayeur, Jean-David Fumet, Sylvain Ladoire, Zoé Tharin, Siavoshe Ayati, Silvia Ilie, Bernard Royer, Antonin Schmitt
Publikováno v:
Pharmaceutics, Vol 13, Iss 10, p 1708 (2021)
Palbociclib is an oral CDK4/6 inhibitor indicated in HR+/HER2- advanced or metastatic breast cancer in combination with hormonotherapy. Its main toxicity is neutropenia. The aim of our study was to describe the kinetics of circulating neutrophils fro
Externí odkaz:
https://doaj.org/article/5646a4677cb04fe080a4b1126b7ca586
Autor:
Sylvain Ladoire, Ariane Mamguem Kamga, Loick Galland, Isabelle Desmoulins, Didier Mayeur, Courèche Kaderbhai, Silvia Mihaelia Ilie, Audrey Hennequin, Clementine Jankowski, Juliette Albuisson, Sophie Nambot, Charles Coutant, Laurent Arnould, Manon Reda, Caroline Truntzer, Sandrine Dabakuyo
Publikováno v:
Breast, Vol 78, Iss , Pp 103789- (2024)
Background: The results of the OlympiA study led to the approval of a PARP inhibitor (olaparib) as adjuvant treatment for early breast cancer (eBC) at high risk of relapse in patients with a germline BRCA1/2 mutation (gBRCAm). However, the proportion
Externí odkaz:
https://doaj.org/article/b67a5194fa204825b8518e79deea3b8e
Autor:
Manon Réda, Anaïs Fouquier, Isabelle Desmoulins, Didier Mayeur, Courèche Kaderbhai, Silvia Ilie, Audrey Hennequin, Bruno Coudert, Aurélie Bertaut, Sylvain Ladoire
Publikováno v:
Breast, Vol 68, Iss , Pp 149-156 (2023)
Background: Taxanes are major drugs for metastatic breast cancer (MBC) treatment, and are generally well tolerated, making them attractive for therapeutic reintroduction (rechallenge) during metastatic course. In view of the paucity of current litera
Externí odkaz:
https://doaj.org/article/d2c8a36ac89a4f8b968b3b3f7d9ac24f
Autor:
Elise Ballot, Loïck Galland, Hugo Mananet, Romain Boidot, Laurent Arnould, Isabelle Desmoulins, Didier Mayeur, Courèche Kaderbhai, Silvia Ilie, Audrey Hennequin, Anthony Bergeron, Valentin Derangère, François Ghiringhelli, Caroline Truntzer, Sylvain Ladoire
Publikováno v:
Breast Cancer Research, Vol 24, Iss 1, Pp 1-16 (2022)
Abstract Purpose The vast majority of research studies that have described the links between DNA damage repair or homologous recombination deficiency (HRD) score, and tumor biology, have concerned either triple negative breast cancers or cancers with
Externí odkaz:
https://doaj.org/article/aae1a74ab7764d138f14f99a0499bf34
Autor:
Loïck Galland, Elise Ballot, Hugo Mananet, Romain Boidot, Julie Lecuelle, Juliette Albuisson, Laurent Arnould, Isabelle Desmoulins, Didier Mayeur, Courèche Kaderbhai, Silvia Ilie, Audrey Hennequin, Anthony Bergeron, Valentin Derangère, François Ghiringhelli, Caroline Truntzer, Sylvain Ladoire
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-12 (2022)
Abstract Metastatic breast cancer (MBC) is frequently managed by platinum-based chemotherapy during the disease course. The real benefit of these treatments is uncertain at advanced stages of the disease and in non-triple-negative subtypes. Since hom
Externí odkaz:
https://doaj.org/article/8c75168bd84843898eaa4679c7af4e30
Autor:
Lorraine Dalens, Julie Lecuelle, Laure Favier, Cléa Fraisse, Aurélie Lagrange, Courèche Kaderbhai, Romain Boidot, Sandy Chevrier, Hugo Mananet, Valentin Derangère, Caroline Truntzer, François Ghiringhelli
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 8; Pages: 7592
Immune checkpoint inhibitors (ICIs) have improved the care of patients in multiple cancer types. However, PD-L1 status, high Tumor Mutational Burden (TMB), and mismatch repair deficiency are the only validated biomarkers of efficacy for ICIs. These m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7f338cb2c1ff4d1e59041301832c8b6
Autor:
sylvain Ladoire, Elise Ballot, Loïck Galland, Hugo Mananet, Romain Boidot, Laurent Arnould, Isabelle Desmoulins, Didier Mayer, Courèche Kaderbhai, Sylvia Ilie, Audrey Hennequin, Anthony Bergeron, Valentin Derangère, Caroline Truntzer, Francois Ghiringhelli
Publikováno v:
Breast Cancer Research. 24
Purpose The vast majority of research studies that have described the links between DNA damage repair or homologous recombination deficiency (HRD) score, and tumor biology, have concerned either triple negative breast cancers or cancers with mutation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::615f4e2a68c72e14c3c9a6a13f621c20
https://doi.org/10.1186/s13058-022-01572-6
https://doi.org/10.1186/s13058-022-01572-6
Autor:
Loïck Galland, Nicolas Roussot, Isabelle Desmoulins, Didier Mayeur, Courèche Kaderbhai, Silvia Ilie, Audrey Hennequin, Manon Reda, Juliette Albuisson, Laurent Arnould, Romain Boidot, Caroline Truntzer, François Ghiringhelli, Sylvain Ladoire
Publikováno v:
Cancers. 15:1299
Breast cancer is the most frequently occurring cancer worldwide. With its increasing incidence, it is a major public health problem, with many therapeutic challenges such as precision medicine for personalized treatment. Thanks to next-generation seq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8c7bdd796fd9712365b6147b3015639
https://doi.org/10.3390/cancers15041299
https://doi.org/10.3390/cancers15041299
Autor:
Loïck Galland, Elise Ballot, Hugo Mananet, Romain Boidot, Julie Lecuelle, Juliette Albuisson, Laurent Arnould, Isabelle Desmoulins, Didier Mayeur, Courèche Kaderbhai, Silvia Ilie, Audrey Hennequin, Anthony Bergeron, Valentin Derangère, François Ghiringhelli, Caroline Truntzer, Sylvain Ladoire
Publikováno v:
NPJ breast cancer. 8(1)
Metastatic breast cancer (MBC) is frequently managed by platinum-based chemotherapy during the disease course. The real benefit of these treatments is uncertain at advanced stages of the disease and in non-triple-negative subtypes. Since homologous r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdf75cb0fee6f67175f2af255c791e20
https://pubmed.ncbi.nlm.nih.gov/35246547
https://pubmed.ncbi.nlm.nih.gov/35246547
Autor:
Francois Ghiringhelli, Romain Boidot, Caroline Truntzer, Bertrand Routy, Philippe Joubert, Julie Lecuelle, Laure Favier, Cléa Fraisse, Aurélie Lagrange, Coureche Kaderbhai, Sandy Chevrier
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background Endogenous retroviruses (ERVs) are highly expressed in various cancer types and are associated with increased innate immune response and better efficacy of antiprogrammed death-1/ligand-1 (anti-PD1/PD-L1)-directed immune checkpoint inhibit
Externí odkaz:
https://doaj.org/article/28eb9d9b877048be85b905e79ee79501